DDInter350 DDInter342
A nitrogen mustard alkylating agent used as antineoplastic agent for the treatment of various malignant and nonmalignant diseases. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed)
Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent complement fixation and antibody-mediated cytotoxicity as well as to markedly increase its half-life. Certolizumab does not require glycosylation for active function and hence, its production is significantly more affordable when compared to other existing TNF-alpha therapies as it can be done directly in bacterial hosts such as _E. coli_. It was developed and manufactured by UCB Pharma, first FDA approved in 2008 and updated for a new indication on March 28, 2019.
Chlorambucil {u} (Compound) resembles {v} (Compound) Melphalan
Melphalan {u} may lead to a major life threatening interaction when taken with {v} Certolizumab pegol
Chlorambucil {u} (Compound) treats {v} (Disease) ovarian cancer
ovarian cancer {u} (Disease) is treated by {v} (Compound) Epirubicin
Epirubicin {u} may lead to a major life threatening interaction when taken with {v} Certolizumab pegol
Chlorambucil {u} (Compound) resembles {v} (Compound) Melphalan
Melphalan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vitamin E
Vitamin E {u} may cause a minor interaction that can limit clinical effects when taken with {v} Certolizumab pegol
Chlorambucil {u} (Compound) resembles {v} (Compound) Melphalan
Melphalan {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc gluconate
Zinc gluconate {u} may cause a minor interaction that can limit clinical effects when taken with {v} Certolizumab pegol
Chlorambucil {u} (Compound) treats {v} (Disease) breast cancer
breast cancer {u} (Disease) is palliated by {v} (Compound) Medroxyprogesterone acetate
Medroxyprogesterone acetate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Certolizumab pegol
Chlorambucil {u} (Compound) resembles {v} (Compound) Melphalan
Melphalan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Candida albicans
Candida albicans {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Certolizumab pegol
Chlorambucil {u} (Compound) binds {v} (Gene) SLCO1A2
SLCO1A2 {u} (Gene) is bound by {v} (Compound) Lovastatin
Lovastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Certolizumab pegol
Chlorambucil {u} (Compound) resembles {v} (Compound) Melphalan
Melphalan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Efalizumab
Efalizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Certolizumab pegol
Chlorambucil {u} (Compound) binds {v} (Gene) GSTP1
GSTP1 {u} (Gene) is bound by {v} (Compound) Etoposide
Etoposide {u} may lead to a major life threatening interaction when taken with {v} Certolizumab pegol
Chlorambucil {u} (Compound) upregulates {v} (Gene) DDB2
DDB2 {u} (Gene) is upregulated by {v} (Compound) Melphalan
Melphalan {u} may lead to a major life threatening interaction when taken with {v} Certolizumab pegol
Chlorambucil (Compound) resembles Melphalan (Compound) and Melphalan may lead to a major life threatening interaction when taken with Certolizumab pegol
Chlorambucil (Compound) treats ovarian cancer (Disease) and ovarian cancer (Disease) is treated by Epirubicin (Compound) and Epirubicin may lead to a major life threatening interaction when taken with Certolizumab pegol
Chlorambucil (Compound) resembles Melphalan (Compound) and Melphalan may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Certolizumab pegol
Chlorambucil (Compound) resembles Melphalan (Compound) and Melphalan may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Certolizumab pegol
Chlorambucil (Compound) treats breast cancer (Disease) and breast cancer (Disease) is palliated by Medroxyprogesterone acetate (Compound) and Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Chlorambucil (Compound) resembles Melphalan (Compound) and Melphalan may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans and Candida albicans may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Chlorambucil (Compound) binds SLCO1A2 (Gene) and SLCO1A2 (Gene) is bound by Lovastatin (Compound) and Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Chlorambucil (Compound) resembles Melphalan (Compound) and Melphalan may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Chlorambucil (Compound) binds GSTP1 (Gene) and GSTP1 (Gene) is bound by Etoposide (Compound) and Etoposide may lead to a major life threatening interaction when taken with Certolizumab pegol
Chlorambucil (Compound) upregulates DDB2 (Gene) and DDB2 (Gene) is upregulated by Melphalan (Compound) and Melphalan may lead to a major life threatening interaction when taken with Certolizumab pegol